13
Mar
2015

Ember Therapeutics, After Shutting Down, Pools IP With Mariel

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices
‘Pharmaphobia’ Pushes Back Against Anti-Industry Crusade, But Comes Up Short
Molecular Information Companies, One Way or Another, Find Value in Genomics
Data From Texas: VCs, Still Mostly Underwater, Ride Stocks As Long As Possible